Recent News

• 03.09.2026 - Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
• 03.09.2026 - Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
• 02.19.2026 - Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 02.19.2026 - Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 02.11.2026 - Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
• 02.04.2026 - Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
• 12.17.2025 - Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
• 12.10.2025 - Veru to Report Fiscal Year 2025 Financial Results on December 17th

Recent Filings

• 02.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.11.2026 - EX-99.1 EX-99.1
• 02.11.2026 - 8-K Current report
• 01.28.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 01.28.2026 - DEF 14A Other definitive proxy statements
• 12.17.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 12.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 12.17.2025 - 8-K Current report
• 12.17.2025 - EX-99.1 EX-99.1